Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Cholangiocarcinoma; Chondrosarcoma; Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 26 Apr 2019 Results (n=168, data cut off: May 12, 2017) published in the Investigational New Drugs
    • 03 Apr 2019 Results detecting IDH1 mutations in plasma cell-free circulating tumor DNA using plasma samples from AG120-C-002 and AG881-C-002 trials presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 16 Mar 2019 Pooled data from 3 studies (NCT02579707, NCT02074839 and NCT02073994) presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top